Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Metagenomi (MGX) Operating Income (2023 - 2025)

Metagenomi (MGX) has disclosed Operating Income for 3 consecutive years, with -$24.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Income fell 18.15% to -$24.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$96.0 million, a 8.0% decrease, with the full-year FY2025 number at -$96.0 million, down 8.0% from a year prior.
  • Operating Income was -$24.4 million for Q4 2025 at Metagenomi, down from -$22.8 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of -$16.9 million in Q2 2024 to a low of -$29.0 million in Q1 2024.
  • A 3-year average of -$22.0 million and a median of -$21.7 million in 2024 define the central range for Operating Income.
  • Biggest YoY gain for Operating Income was 6.12% in 2024; the steepest drop was 61.85% in 2024.
  • Metagenomi's Operating Income stood at -$20.2 million in 2023, then dropped by 2.11% to -$20.6 million in 2024, then dropped by 18.15% to -$24.4 million in 2025.
  • Per Business Quant, the three most recent readings for MGX's Operating Income are -$24.4 million (Q4 2025), -$22.8 million (Q3 2025), and -$21.0 million (Q2 2025).